盐酸西那卡塞专利分析

Patent analysis of cinacalcet hydrochloride

盐酸西那卡塞是全球第1个拟钙剂,由安进公司从NPS制药公司获得授权开发。本文对该盐酸西那卡塞药物进行专利检索和分析,重点关注其核心专利、布局专利、相关专利纠纷的情况,以期为我国医药企业在药物专利挖掘、布局时提供信息参考,具有一定的参考借鉴价值。本文获得以下启示:利用专利延长制度和选择专利申请时机,能有效延长药品的市场独占期;从外部引入产品后,制药企业应当积极开展创新探索、专利布局,以建立严密的专利围墙。

Cinacalcet hydrochloride is the first commercially available calciumimetic agent. Amgen obtained it through authorization from NPS Pharmaceutical. This study searches and analyzes the patents of cinacalcet, focusing on its core patents, layout patents, and related patent disputes, in order to provide information references for Chinese pharmaceutical enterprises in drug patent mining and layout. This study obtains the following insights: by utilizing the patent extension system and selecting the timing of patent applications, the market monopoly period of drugs can be effectively extended;after introducing projects from outside, pharmaceutical companies should actively carry out innovation exploration and patent layout to establish a strict patent wall.